Technical Analysis for FREQ - Frequency Therapeutics, Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
 |
15.44 | 1.31% | 0.20 |
FREQ closed up 1.31 percent on Friday, December 6, 2019, on approximately normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.
| ADX | Long-Term | Intermediate-Term | Short-Term |
|---|---|---|---|
| Weak or Absent | N/A | N/A | Down |
| See historical FREQ trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| NR7 | Range Contraction | 0.00% | |
| NR7-2 | Range Contraction | 0.00% | |
| Stochastic Reached Oversold | Weakness | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| NR7 | Range Contraction | 1.31% | |
| Inside Day | Range Contraction | 1.31% | |
| Down 3 Days in a Row | Weakness | 1.31% | |
| 20 DMA Resistance | Bearish | -0.77% | |
| Bearish Engulfing | Bearish | -1.91% | |
| Fell Below 20 DMA | Bearish | -1.91% |
Free Daily (Stock) Chart Reading
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: ???
- Sector: Healthcare
- Industry: Biotechnology
Frequency Therapeutics is a clinical-stage biotechnology company focused on harnessing the body’s innate biology to repair or reverse damage caused by a broad range of degenerative diseases. Frequency’s progenitor cell activation (PCA) approach stimulates progenitor cells to create functional tissue with the aim of developing disease modifying therapeutics. The company’s lead product candidate, FX-322, is in clinical development and is designed to regenerate auditory hair cells to restore hearing function in patients with sensorineural hearing loss, the most common form of hearing loss. The company is also evaluating its PCA approach in additional diseases, including multiple sclerosis.
Biotechnology Medical Specialties Disease Multiple Sclerosis Occupational Safety And Health Perception Degenerative Diseases Hearing Loss Audiology Auditory System Hearing Sensorineural Hearing Loss
Biotechnology Medical Specialties Disease Multiple Sclerosis Occupational Safety And Health Perception Degenerative Diseases Hearing Loss Audiology Auditory System Hearing Sensorineural Hearing Loss
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
See more FREQ news...
| Indicator | Value |
|---|---|
| 52 Week High | 17.44 |
| 52 Week Low | 11.17 |
| Average Volume | 112,801 |
| 200-Day Moving Average | 0.00 |
| 50-Day Moving Average | 0.00 |
| 20-Day Moving Average | 15.90 |
| 10-Day Moving Average | 16.08 |
| Average True Range | 0.99 |
| ADX | 17.64 |
| +DI | 15.21 |
| -DI | 18.15 |
| Chandelier Exit (Long, 3 ATRs ) | 14.47 |
| Chandelier Exit (Short, 3 ATRs ) | 17.25 |
| Upper Bollinger Band | 17.13 |
| Lower Bollinger Band | 14.66 |
| Percent B (%b) | 0.31 |
| BandWidth | 15.52 |
| MACD Line | 0.33 |
| MACD Signal Line | 0.54 |
| MACD Histogram | -0.2134 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 16.34 | ||||
| Resistance 3 (R3) | 16.36 | 16.08 | 16.19 | ||
| Resistance 2 (R2) | 16.08 | 15.85 | 16.07 | 16.14 | |
| Resistance 1 (R1) | 15.76 | 15.71 | 15.62 | 15.74 | 16.09 |
| Pivot Point | 15.48 | 15.48 | 15.41 | 15.47 | 15.48 |
| Support 1 (S1) | 15.16 | 15.25 | 15.02 | 15.14 | 14.79 |
| Support 2 (S2) | 14.88 | 15.11 | 14.87 | 14.74 | |
| Support 3 (S3) | 14.56 | 14.88 | 14.69 | ||
| Support 4 (S4) | 14.54 |
